Lindgren B W, Demos T, Marsan R, Posniak H, Kostro B, Calvert D, Hatch D, Flanigan R, Steinmuller D, Lewis R
Department of Urology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Transplantation. 1996 Jan 27;61(2):219-23. doi: 10.1097/00007890-199601270-00010.
Renal computed tomography (CT), 3-dimensional CT angiography (3D-CTA), and simultaneous measurement of glomerular filtration rate (GFR) by x-ray fluorescence determination of plasma contrast clearance (PCC) are alternatives to intravenous urography (IVU), renal arteriography (RA), and 24-hr urine creatinine clearance (CrCl) for evaluation of renal structure and function in living renal donor (LRD) candidates. To determine if CT, 3D-CTA, and PCC provide data comparable to IVU, RA, and CrCl, both methods were used to evaluate 23 LRD candidates. Costs were also compared. Conventional RA identified 19 accessory arteries and one case of medial fibroplasia. Each of these anomalous vessels was recognized on 3D-CTA. Venous anatomy was more clearly delineated on 3D-CTA than the venous phase of conventional RA. CT demonstrated 3 benign cysts and a single, small intraparenchymal calcification in 3 renal units. GFRs measured by PCC and CrCl were 91 +/- 4 and 132 +/- 7 ml/min/1.73m2, respectively (r = 0.64, P < 0.05). Total cost for CT/3D-CTA/PCC was 46% less than that of IVU/RA/CrCl and 40% less than RA/CrCl. CT/3D-CTA/PCC provided reliable structural and functional data at substantially less cost, discomfort, and inconvenience to the living renal donor candidate. As such, CT/3D-CTA/PCC is superior to conventional methods for evaluation of the living renal donor candidate.
肾脏计算机断层扫描(CT)、三维CT血管造影(3D - CTA)以及通过X射线荧光测定血浆造影剂清除率(PCC)同步测量肾小球滤过率(GFR),是替代静脉肾盂造影(IVU)、肾动脉造影(RA)和24小时尿肌酐清除率(CrCl)的方法,用于评估活体肾供体(LRD)候选者的肾脏结构和功能。为了确定CT、3D - CTA和PCC所提供的数据是否与IVU、RA和CrCl相当,两种方法都用于评估23名LRD候选者。同时还比较了成本。传统的RA识别出19条副动脉和1例内侧纤维增生。这些异常血管在3D - CTA上均被识别。3D - CTA对静脉解剖结构的显示比传统RA的静脉期更清晰。CT在3个肾单位中发现了3个良性囊肿和1个小的肾实质内钙化。通过PCC和CrCl测量的GFR分别为91±4和132±7 ml/min/1.73m²(r = 0.64,P < 0.05)。CT/3D - CTA/PCC的总成本比IVU/RA/CrCl低46%,比RA/CrCl低40%。CT/3D - CTA/PCC以显著更低的成本、更少的不适和不便为活体肾供体候选者提供了可靠的结构和功能数据。因此,CT/3D - CTA/PCC在评估活体肾供体候选者方面优于传统方法。